Medical News Podcast

Drs. Clayton and Payne review strategies for the identification and diagnosis of PPD. They discuss screening, diagnostic criteria, and differential diagnosis, among other topics.

In this podcast, a study from Ontario revealed that SGLT2 inhibitors, when combined with statins, were associated with a 25% lower risk of rhabdomyolysis compared to DPP4 inhibitors. A phase I trial at Washington University demonstrated promising outcomes for a neoantigen DNA vaccine aimed at preventing recurrence in triple-negative breast cancer (TNBC). Finally, intensive systolic blood pressure...

Drs. Payne and Clayton review in detail the management of patients with postpartum depression; discussing specific agents and classes of drugs, as well as nonpharmacological interventions and holistic and complementary approaches.

Drs. Siri and Jacobs discuss the biological treatment of patients with food allergies, reviewing currently available options, combination with immunotherapy, and other emerging therapies.

Drs. Siri and Jacobs discuss a typical case of a 4-year-old patient with peanut allergy, reviewing diagnostic and management strategies, as well as considerations such as age, IgE levels, oral food challenge, and current therapies.

Michael Putman, MD, MSci and Zachary Wallace, MD, MSc discuss a personalized approach to managing the treatment of patients with ANCA-associated vasculitis, including the role of ANCA type and titers and their impact on flare risk and treatment decisions.

NEJM reports on the safety of very early medication abortion, showing that initiating abortion medication before ultrasound confirmation is as effective and safe as the standard approach, reducing barriers in restricted settings. Another study highlighted the long-term survival impact of combining dabrafenib and trametinib for resected stage III melanoma patients with *BRAF* V600 mutations, noting...

Drs. Zachary Wallace and Michael Putman continue their induction therapy discussion in patients with ANCA-associated vasculitis, reviewing the use of glucocorticoids, avacopan, and plasma exchange.

Sami Diab, MD and Tejas Patil, MD continue their discussion about emerging treatments for HER2+ lung cancer, including data presented from DESTINY-Lung03, liquid biopsies, emerging resistance, and treatment sequencing..

Michael Putman, MD, MSci and Zachary Wallace, MD, MSc review induction chemotherapy in patients with ANCA-associated vasculitis, focusing on the use of cyclophosphamide and rituximab.

Anisha B. Dua, MD, MPH and Duvuru Geetha, MD discuss evolving strategies in maintenance therapy for ANCA-associated vasculitis. In keeping with the goal of achieving sustained remission and minimizing relapse, they provide insight into the duration and dosing of maintenance therapy, as well as treatment options and monitoring.

Anisha B. Dua, MD, MPH and Duvuru Geetha, MD share their insights into the nuances of steroid reduction and steroid-sparing approaches in ANCA-associated vasculitis treatment protocols, including the clinical benefits of steroid reduction, options available, and which patients might be the best candidates for steroid reduction.

Drs. Diab and Patil discuss recent advances in treating HER2+ lung cancer that were presented at World Lung 2024 and ESMO 2024. They highlight the role of newer treatments and discuss treatment sequencing and response rates.

Drs. Dua and Geetha share their insights into the renal manifestations of ANCA-associated vasculitis, detailing how kidney function is affected. They also delve into the recent guideline updates on the diagnosis and management of ANCA-associated vasculitis.

Drs. Bilezikian and Cosman examine goal-directed strategies and treatment targets for the long-term management of fracture risk in patients with osteoporosis, including how they choose treatment goals for their patients within differing risk groups. They also discuss the importance of T-scores in assessing patient risk.

Drs. Cosman and Bilezikian continue their discussion by sharing how they determine whether treatment targets for their patients have been met and how that differs from treatment response. They explore how they evaluate patients with osteoporosis, how they utilize surrogate markers in their practices, and what their personal strategies are for achieving treatment goals.

Drs. Benjamin Schlechter and Harshabad Singh discuss HER2-low and ultralow in GI cancers, newer therapies targeting HER2, and testing methods for HER in GI cancers.

Drs. Benjamin Schlechter and Harshabad Singh discuss toxicities in gastroesophageal cancer treatment; explore HER2+ in biliary tract tumors; and touch on the challenges of developing therapies targeting HER2+.

A study links poor sleep quality with accelerated neurodegenerative changes, suggesting that persistent sleep disturbances may expedite brain atrophy, warranting early therapeutic interventions to support cognitive health. Concurrently, data from JAMA Network Open Psychiatry reveal that social media use has complex effects on youth mental health, with excessive screen time and cyberbullying increa...

Drs. Benjamin Schlechter and Harshabad Singh explore the role and function of HER2 in gastrointestinal cancers, with a focus on gastroesophageal and colorectal cancers.

Drs. Bilezikian and Cosman discuss the use of anabolic agents in patients with postmenopausal osteoporosis, including the benefits and challenges of utilizing anabolic agents as well as the need for careful patient selection, education. and monitoring. They also review the mechanisms of action, clinical trial data, and rationale of treatment sequencing.

Drs. Cosman and Bilezikian discuss the optimal use of denosumab in patients with postmenopausal osteoporosis and examine how RANK ligand inhibitors differ from bisphosphonate medications. They also share insight into how they personalize therapy with denosumab in patients with postmenopausal osteoporosis.

Drs. Dietrich and Holloway continue sharing their insights into the pivotal role of HER2 positivity in gynecologic cancers. They discuss how HER2, a well-known biomarker in breast cancer, is increasingly recognized for its significance in other gynecologic malignancies, including ovarian and endometrial cancers.

Drs. Dietrich and Holloway share their insights into the pivotal role of HER2 positivity in gynecologic cancers. They discuss how HER2, a well-known biomarker in breast cancer, is increasingly recognized for its significance in other gynecologic malignancies, including ovarian and endometrial cancers.

Martin Dietrich, MD, PhD and Robert Holloway, MD continue their conversation about the biological and clinical significance of HER2+ receptors in these diverse malignancies, collectively referred to as pan-tumors, as well as the implications of HER2 that are crucial for advancing approaches to diagnosis, treatment, and patient care across various cancer types.